ClinicalTrials.gg
CompletedNCT05987228Updated Aug 14, 2023

Effects of Orally Administered Thymus Vulgaris Leaves on Memory, Anxiety, Depression, and Sleep Quality in University Students: A Randomized Controlled Trial

An interventional study of Thymus vulgaris in Memory Dysfunction, Anxiety and Depression, sponsored by The Hashemite University. Completed at 1 site in Jordan. Open to participants aged 19 Years to 23 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Hashemite University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2022, registered Aug 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
19 Years to 23 Years
Sex
All
01

Study summary

Thymus vulgaris could potentially serve as a safer alternative to stimulant drugs for enhancing memory among university students. Furthermore, Thymus vulgaris may offer additional benefits in terms of reducing anxiety, depression, and improving sleep quality. However, it should be noted that the current research on the effects of orally administered Thymus vulgaris on the brain and nervous system is limited, and further studies are required to fully explore its potential advantages. Therefore, the purpose of this study is to investigate the effects of oral Thymus vulgaris on memory performance, anxiety, depression, and sleep quality in university students.

Read the detailed description

Thymus vulgaris belongs to the Lamiaceae family and is a flowering plant. It can be found worldwide, although its origin is in southern Europe [1]. This plant is characterized by its compact, bushy nature and evergreen shrub structure. Its leaves are small, gray-green, highly aromatic, and it produces clusters of purple or pink flowers [2]. Thymus vulgaris is commonly used as a spice to enhance the flavor of food. It is also utilized in the form of dietary supplements; such as capsules or essential oils [3]. Throughout history, Thymus vulgaris has been employed in folk medicine due to its remarkable antimicrobial and anti-inflammatory properties [4]. In Jordanian traditional medicine, it is frequently utilized as an antiseptic, bronchial, sedative, and spasmolytic agent, as well as to improve cognitive function and memory [5-8]. Numerous studies have reported various health benefits associated with Thymus vulgaris leaves, including antioxidant [9], diuretic [10], anti-inflammatory [11], antiviral [12], anti-cancerous [13], cholesterol-lowering [14], glucose-lowering [15], anticonvulsant [16], anti-anxiety [17] and sedative-hypnotic activities [18].

The primary constituents of Thymus vulgaris, notably thymol, p-cymene, γ-terpinene, linalool, and carvacrol, possess various neuropharmacological properties, including anti-anxiety, sedative, anticonvulsant, memory-enhancing, and anti-Alzheimer's disease effects [19]. Asadbegi et al. conducted a study demonstrating that thymol exhibited neuroprotective properties by reducing memory impairment caused by intrahippocampal injection of the amyloid beta (Aβ) peptide in rats fed a high-fat diet [20]. Furthermore, Capibaride et al. confirmed the significant antidepressant-like effect of thymol by observing its ability to reverse behaviors associated with chronic corticosterone exposure and decrease in BDNF levels in female mice [21]. Azizi et al. demonstrated that carvacrol and thymol exerted neuroprotective effects against Aβ25-35-induced damage, potentially through the attenuation of oxidative stress and the modulation of PKC activity, a protein associated with memory function [22]. Additionally, within the monoterpenes and sesquiterpenes, β-myrcene and caryophyllene have been identified as major compounds. β-myrcene is known for its analgesic, anxiolytic, and anti-inflammatory effects [23].

Multiple studies have highlighted the positive impact of Thymus vulgaris on memory, anxiety, and depression. Akan et al. conducted research on rats using the Morris water maze and found that Thymus vulgaris L. exhibited beneficial effects against diabetes mellitus-induced neuropathy and cognitive impairment [24]. They attributed these effects to specific components like thymol, carvacrol, 8-terpinene, p-cymene, and α-pinene present in high amounts in the essential oil composition. Similarly, Rabiei et al. suggested that Thymus vulgaris extract demonstrated anti-amnesic properties in rats with Sco-induced memory deficits, as assessed by the Morris water maze and passive avoidance tests [25]. The authors proposed that this effect could be linked to the extract's antioxidant activity or its influence on the cholinergic system, with carvacrol and thymol playing significant roles based on their chemical composition. Additionally, an ethanol extract derived from Thymus vulgaris leaves displayed an anxiolytic profile in rats during the EPM test, unaffected by locomotor activity [17]. Finally, in the context of Alzheimer's disease, a neurodegenerative disorder involving cholinergic neuron loss, administration of thyme oil to Caenorhabditis elegans enhanced neurotransmission by regulating synaptic acetylcholine levels [26].

The high prevalence of anxiety, depression, and sleep disorders among university students can significantly affect their memory function [27]. Consequently, an increasing number of university students have turned to using stimulant drugs to improve their memory performance and attention, despite the fact that such usage is unauthorized and not intended for therapeutic purposes [28]. However, the use of these drugs is associated with various side effects[29,30]. This has led neuroscience researchers to show a growing interest in identifying cognitive-enhancing drugs that can be safely used by healthy individuals without any detrimental effects.

Based on the provided information, it is hypothesized that Thymus vulgaris could potentially serve as a safer alternative to stimulant drugs for enhancing memory among university students. Furthermore, Thymus vulgaris may offer additional benefits in terms of reducing anxiety, depression, and improving sleep quality. However, it should be noted that the current research on the effects of orally administered Thymus vulgaris on the brain and nervous system is limited, and further studies are required to fully explore its potential advantages. Therefore, the purpose of this study is to investigate the effects of oral Thymus vulgaris on memory performance, anxiety, depression, and sleep quality in university students.

02

Conditions studied

  • Memory Dysfunction
  • Anxiety
  • Depression
  • Sleep

Browse trials for

Keywords

  • Thymus vulgaris leaves
  • Memory performance
  • Anxiety
  • Depression
  • Sleep
03

In context

Depression Reclassified

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's enrollment of 86 is close to the median of 81 across 7,063 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

The Hashemite University is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
19 Years to 23 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health participants

Exclusion criteria

Exclusion Criteria:

  • individuals with medical diseases, psychiatric disorders, those using any medications (including complementary and alternative medicines), as well as pregnant and lactating individuals, were excluded from participating
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Thymus vulgaris group

    500 mg of Thymus vulgaris (capsules) was given orally twice daily

    Dietary Supplement: Thymus vulgaris

  • Placebo comparator
    control group

    500 mg starch (capsules) was given orally twice daily

    Dietary Supplement: Thymus vulgaris

Interventions

  • Dietary supplementThymus vulgaris

    500 mg of Thymus vulgaris (capsules) was given orally twice daily

06

What researchers measure

Primary outcomes

  1. Memory performance

    Prospective and Retrospective Memory Questionnaire (PRMQ) was employed

    Time frame: 30 days

Secondary outcomes

  1. Anxiety and depression

    Anxiety and depression levels were measured using the Hospital Anxiety and Depression Scale (HADS)

    Time frame: 30 days

  2. Sleep quality

    Pittsburgh Sleep Quality Inventory (PSQI) questionnaire was performed

    Time frame: 30 days

07

Study locations

1 site
  • Faculty of Pharmaceutical Sciences
    Zarqa, 13133, Jordan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05987228
Lead sponsor
The Hashemite University
Responsible party
Abdelrahim Alqudah (Assisstant professor, The Hashemite University) — Principal investigator
First posted
Aug 14, 2023
Start date
Aug 1, 2022
Primary completion
Dec 1, 2022
Completion
Dec 1, 2022
Last update
Aug 14, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion